Core Insights - The U.S. naloxone market has annual sales of approximately $154 million, with a unit volume of 9.3 million units [3] Company Overview - Scienture Holdings, Inc. is a holding company focused on developing, commercializing, and distributing specialty pharmaceutical products to meet unmet market needs [8] - Scienture, LLC, a wholly owned subsidiary, has entered into an exclusive agreement with Summit Biosciences for the U.S. commercialization rights of REZENOPY [2][8] Product Launch - REZENOPY is a high-strength naloxone HCl nasal spray (10 mg) approved by the FDA, designed for emergency treatment of opioid overdose [3][5] - The product is expected to be ready for wholesale distribution in Q1 2026, with commercial availability anticipated in early Q2 2026 [4] Market Positioning - REZENOPY is positioned as the highest-strength naloxone available, intended for patients who may require multiple doses of lower-strength naloxone [4] - The product aims to address critical needs in overdose situations involving potent opioids [4]
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA